BioCentury
ARTICLE | Distillery Therapeutics

Cancer

May 15, 2018 6:06 PM UTC

Mouse studies suggest nanoparticles loaded with an ADORA2A antagonist and conjugated to CAR T cells could help treat ovarian cancer. The conjugate consists of cross-linked multilamellar liposomal nanoparticles loaded with a tool compound ADORA2A antagonist and linked to CAR T cells with a maleimide-thiol bridge. In a mouse model of ovarian cancer, the conjugate decreased tumor growth and increased T cell engraftment in the tumor and survival compared with the CAR T cells alone or the unconjugated antagonist-loaded liposomes and CAR T cells. In a mouse model of ovarian cancer pretreated with CAR T cells, the conjugate decreased tumor size and increased the number of tumor-infiltrating T cells, including the CAR T cells. Next steps could include testing the conjugate in models of other cancers.

Kyowa Hakko Kirin Co. Ltd. markets the ADORA2A antagonist Nouriast istradefylline to treat Parkinson’s disease...